Program
AZD7760
A development code.
Its studies are mostly in Staphylococcal Infections · Sepsis, led by AstraZeneca.
Furthest: phase 2, since Dec 23, 20242 company-led studies, 2 open or runningNext primary completion: Mar 8, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 22 open or running | phase 2since Dec 23, 2024 | Dec 23, 2024 | Mar 8, 2027phase 2 · NCT06749457 |
- Named in AstraZeneca’s own pipeline as
AZD7760
, phase 2, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 23, 2024First study: phase 2 study in Staphylococcal InfectionsFirst studyNCT06749457 · 242 enrolled · United States
- May 21, 2026Phase 1 study in Staphylococcus Aureus Bloodstream InfectionNCT07612813 · 18 enrolled · Japan
Ahead
- Mar 8, 2027Primary completion: phase 2 study in Staphylococcal InfectionsNCT06749457
- Sep 13, 2027Primary completion: phase 1 study in Staphylococcus Aureus Bloodstream InfectionNCT07612813
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07612813Staphylococcus Aureus Bloodstream Infection · Japan | 1 | Active, not recruiting | Sep 13, 2027 | 18 |
| NCT06749457Staphylococcal Infections · United States | 2 | Active, not recruiting | Mar 8, 2027 | 242 |
How it is read
Names in the registry
- “AZD7760”, 2 entries
Codes read as this program: AZD7760.
Conditions, from the studies’ own filings
- Staphylococcal Infections, 1 study
- Sepsis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.